In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. GEVA, and raised its price target from $42.00 to $50.00.
Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”
Synageva BioPharma Corp. closed on Tuesday at $42.85.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in